SAS Output

14-DEC-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 248 235 46 17 14 7 2 09/19/2014 235 99
            235 46 17 14 7 2      
 
    2 Y 2 Continuous Dosing 216 96 21 5 2 1 0 09/19/2014    
        3 Intermittent Dosing   91 18 4 1 1 0      
            187 39 9 3 2 0      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 18 14 8 4 1 0 02/06/2017 89 41
            18 14 8 4 1 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 8 8 7 6 1 0 06/05/2018 34 18
            8 8 7 6 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 8 7 4 0 0 0 10/23/2017 247 97
        2 Nivolumab + Ipilimumab   19 17 9 4 1 0      
            27 24 13 4 1 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   31 6 4 2 0 0 11/03/2015 362 143
            31 6 4 2 0 0      
 
    2 E Total Registrations   12 7 5 1 0 0 11/03/2015    
            12 7 5 1 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 224 93
            36 0 0 0 0 0      
 

14-DEC-2018 6:10

MELAN Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Randomization 06-Dec-18
  2 Surgery 06-Dec-18
  3 Adjuvant Therapy 06-Dec-18